MGI and SeqOne’s mission is to to broaden access to sophisticated genomic analysis. Image credit: Shutterstock / Juan Ci.

Chinese biotech MGI Tech and France’s SeqOne Genomics are partnering to advance an end-to-end solution for genomic testing.

SeqOne’s AI-driven genomic decision support platform, SeqOne Platform, and MGI’s DNBSEQ-G99 genome sequencer will be combined to investigate several efficiencies to the gene analysis process.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The companies aim to create an end-to-end solution for homologous recombination deficiency (HRD) testing including genomic instability scores and breast cancer (BRCA) gene testing.

HRD is a cellular state in which cells cannot repair double-strand DNA breaks (DSBs) using the homologous recombination (HR) pathway. A key indicator of a tumour’s response to certain treatments, HRD is especially prevalent in advanced ovarian cancer.

To achieve this, the companies will collaborate with Spanish pathology reference lab Agilent Technologies, testing 96 sample panels from Agilent’s next-generation sequencing (NGS) platform, Magnis NGS.

See Also:

The companies will also be looking to validate the compatibility of SeqOne’s CE-IVD platform for germline and somatic analysis with MGI’s routine diagnostics sequencers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Guidance from the American Society for Clinical Oncology (ASCO) is increasingly recommending that testing germline in NGS be utilised to assess for BRCA1/2 in homologous recombination repair (HRR) genes.

The companies also plan to make MegaBOLT, MGI’s hardware accelerating system for bioinformatics analysis, compatible with SeqOne’s AI-powered variants identification and analysis solution to speed up the time between sampling and reporting within genetics labs.

“By combining MGI’s cutting-edge sequencing technology with SeqOne’s innovative genomic analysis platform, we are poised to deliver real insights and solutions for personalised healthcare,” said general manager of MGI Europe and Africa Dr. Yong Hou.

Around 190 NGS devices are in various stages of development globally, according to GlobalData’s medical device pipeline database, with 127 in active development, including 59 in early-stage and 68 in late-stage development.

In 2023, Exact Sciences launched its OncoExTra NGS device in the US.

AstraZeneca Spain recently selected cloud-native software company Sophia Genetics as its preferred partner for expanding HRD testing for ovarian cancer across Spain, with the aim of making HRD testing accessible to more laboratories.